11. Induction of p53 suppresses chronic myeloid leukemia. Issue 9 (2nd September 2017) Authors: Peterson, Luke F.; Lo, Miao-Chia; Liu, Yihong; Giannola, Diane; Mitrikeska, Emilija; Donato, Nicholas J.; Johnson, Craig N.; Wang, Shaomeng; Mercer, Jessica; Talpaz, Moshe Journal: Leukemia & lymphoma Issue: Volume 58:Issue 9(2017) Page Start: 2165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Issue 7 (July 2017) Authors: Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Tiu, Ramon V; Zachee, Pierre; Jourdan, Eric; Winton, Elliott; Silver, Richard T; Schouten, Harry C; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Lager, Joanne; Shun, Zhenming; Mesa, Ruben A Journal: Lancet Issue: Volume 4:Issue 7(2017) Page Start: e317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Meir Wetzler, MD. Issue 13 (1st April 2015) Authors: Kurzrock, Razelle; Estrov, Zeev; Talpaz, Moshe; Kantarjian, Hagop M. Journal: Cancer Issue: Volume 121:Issue 13(2015) Page Start: 2106 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Overcoming resistance in chronic myeloid leukemia. (September 2013) Authors: Roy, Rupali; Talpaz, Moshe Journal: Clinical investigation Issue: Volume 3:Number 9(2013) Page Start: 817 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. Issue 5 (29th May 2021) Authors: Mesa, Ruben A.; Schaap, Nicolaas; Vannucchi, Alessandro M.; Kiladjian, Jean-Jacques; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Abraham, Pranav; Lord-Bessen, Jennifer; Tang, Derek; Guo, Shien; Ye, Xiaomei; Harrison, Claire N. Journal: HemaSphere Issue: Volume 5:Issue 5(2021) Page Start: e553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. (April 2019) Authors: Gerds, Aaron T.; Tauchi, Tetsuzo; Ritchie, Ellen; Deininger, Michael; Jamieson, Catriona; Mesa, Ruben; Heaney, Mark; Komatsu, Norio; Minami, Hironobu; Su, Yun; Shaik, Naveed; Zhang, Xiaoxi; DiRienzo, Christine; Zeremski, Mirjana; Chan, Geoffrey; Talpaz, Moshe Journal: Leukemia research Issue: Volume 79(2019) Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia. Issue 11 (30th August 2022) Authors: Kantarjian, Hagop M.; Jabbour, Elias; Deininger, Michael; Abruzzese, Elisabetta; Apperley, Jane; Cortes, Jorge; Chuah, Charles; DeAngelo, Daniel J.; DiPersio, John; Hochhaus, Andreas; Lipton, Jeffrey; Nicolini, Franck E.; Pinilla‐Ibarz, Javier; Rea, Delphine; Rosti, Gianantonio; Rousselot, Philip... Journal: American journal of hematology Issue: Volume 97:Issue 11(2022) Page Start: 1419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. (21st May 2013) Authors: Shah, Neil P.; Talpaz, Moshe; Deininger, Michael W. N.; Mauro, Michael J.; Flinn, Ian W.; Bixby, Dale; Lustgarten, Stephanie; Gozgit, Joseph M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; Kantarjian, Hagop; Cortes, Jorge E. Journal: British journal of haematology Issue: Volume 162:Number 4(2013:Aug.) Page Start: 548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Issue 5 (May 2016) Authors: Lipton, Jeffrey H; Chuah, Charles; Guerci-Bresler, Agnès; Rosti, Gianantonio; Simpson, David; Assouline, Sarit; Etienne, Gabriel; Nicolini, Franck E; le Coutre, Philipp; Clark, Richard E; Stenke, Leif; Andorsky, David; Oehler, Vivian; Lustgarten, Stephanie; Rivera, Victor M; Clackson, Timothy; Ha... Journal: Lancet oncology Issue: Volume 17:Issue 5(2016:May) Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Issue 4 (21st March 2019) Authors: Menghrajani, Kamal; Boonstra, Philip S.; Mercer, Jessica A.; Perkins, Cecelia; Gowin, Krisstina L.; Weber, Alissa A.; Mesa, Ruben; Gotlib, Jason R.; Wang, Lixia; Singer, Jack W.; Talpaz, Moshe Journal: Leukemia & lymphoma Issue: Volume 60:Issue 4(2019) Page Start: 1036 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗